{
    "clinical_study": {
        "@rank": "43450", 
        "acronym": "DS201", 
        "arm_group": [
            {
                "arm_group_label": "ELND005 BID", 
                "arm_group_type": "Experimental", 
                "description": "ELND005 250 mg BID"
            }, 
            {
                "arm_group_label": "ELND005 QD", 
                "arm_group_type": "Experimental", 
                "description": "ELND005 250 mg QD"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo BID"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomized, double-blind, placebo-controlled, parallel-group,\n      three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4\n      weeks.  This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive)\n      without dementia."
        }, 
        "brief_title": "A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Down Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dementia", 
                "Down Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 - 45 years of age\n\n          -  Has an IQ of > 40 (K-BIT)\n\n          -  Able and willing to have a brain MRI\n\n        Exclusion Criteria:\n\n          -  Symptoms of dementia or worsening cognition over the past year.\n\n          -  Has a history of hepatitis B, hepatitis C, or HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791725", 
            "org_study_id": "ELND005-DS201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ELND005 BID", 
                    "ELND005 QD"
                ], 
                "intervention_name": "ELND005", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92093-0949"
                    }, 
                    "name": "University of California, San Diego"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "University of California, Irvine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia", 
        "other_outcome": [
            {
                "description": "Rapid Assessment for Development Disabilities (RADD)", 
                "measure": "Cognitive Outcome", 
                "safety_issue": "No", 
                "time_frame": "4 Weeks"
            }, 
            {
                "description": "Vineland Adaptive Behavior Scale, Second Edition (VABS-II)", 
                "measure": "Functional Outcomes", 
                "safety_issue": "No", 
                "time_frame": "4 Weeks"
            }
        ], 
        "overall_contact": {
            "email": "patrick.kesslak@elan.com", 
            "last_name": "Patrick Kesslak, Ph D", 
            "phone": "415-590-0078"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events (TEAE, SAE)", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Changes from Baseline in physical and neurological examinations", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791725"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "ELND005 PK profile to optimize PK model including patient population", 
            "measure": "Plasma ELND005 concentrations", 
            "safety_issue": "No", 
            "time_frame": "4 Weeks"
        }, 
        "source": "Elan Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Elan Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Elan Pharma International Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}